Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Vaccination | Research

Sustained circulation of yellow fever virus in Cameroon: an analysis of laboratory surveillance data, 2010–2020

Authors: Fredy Brice Simo Nemg, Ngu Njei Abanda, Martial Gide Yonga, Diane Ouapi, Ivis Ewang Samme, Marlise Dontsop Djoumetio, Marie Claire Endegue-Zanga, Maurice Demanou, Richard Njouom

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

The re-emergence of yellow fever poses a serious public health risk to unimmunized communities in the tropical regions of Africa and South America and unvaccinated travelers visiting these regions. This risk is further accentuated by the likely spread of the virus to areas with potential for yellow fever transmission such as in Asia, Europe, and North America. To mitigate this risk, surveillance of yellow fever is pivotal. We performed an analysis of laboratory-based surveillance of yellow fever suspected cases in Cameroon during 2010–2020 to characterize the epidemiology of yellow fever cases and define health districts at high risk.

Method

We reviewed IgM capture ELISA and plaque reduction neutralization test (PRNT) test results of all suspected yellow fever patients analyzed at Centre Pasteur of Cameroon, the national yellow fever testing laboratory, during 2010–2020.

Results

Of the 20,261 yellow fever suspected patient’s samples that were tested, yellow fever IgM antibodies were detected in 360 patients representing an annual average of 33 cases/year. A major increase in YF IgM positive cases was observed in 2015 and in 2016 followed by a decrease in cases to below pre-2015 levels. The majority of the 2015 cases occurred during the latter part of the year while those in 2016, occurred between February and May. This trend may be due to an increase in transmission that began in late 2015 and continued to early 2016 or due to two separate transmission events. In 2016, where the highest number of cases were detected, 60 health districts in the 10 regions of Cameroon were affected with the Littoral, Northwest and, Far North regions being the most affected. After 2016, the number of detected yellow fever IgM positive cases dropped.

Conclusion

Our study shows that yellow fever transmission continues to persist and seems to be occurring all over Cameroon with all 10 regions under surveillance reporting a case. Preventive measures such as mass vaccination campaigns and routine childhood immunizations are urgently needed to increase population immunity. The diagnostic limitations in our analysis highlight the need to strengthen laboratory capacity and improve case investigations.
Appendix
Available only for authorised users
Literature
2.
go back to reference Gaythorpe KAM, Hamlet A, Jean K, Ramos DG, Cibrelus L, Garske T, et al. The global burden of yellow fever. eLife. 2021;10. Gaythorpe KAM, Hamlet A, Jean K, Ramos DG, Cibrelus L, Garske T, et al. The global burden of yellow fever. eLife. 2021;10.
3.
4.
6.
go back to reference Kraemer MUG, Faria NR, Reiner RC, Golding N, Nikolay B, Stasse S, et al. Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015–16: a modelling study. Lancet Infect Dis. 2017;17(3):330–8. http://www.worldpop.org.uk/. Accessed 1 Jun 2021. Kraemer MUG, Faria NR, Reiner RC, Golding N, Nikolay B, Stasse S, et al. Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015–16: a modelling study. Lancet Infect Dis. 2017;17(3):330–8. http://​www.​worldpop.​org.​uk/​. Accessed 1 Jun 2021.
8.
go back to reference Garske T, Van Kerkhove MD, Yactayo S, Ronveaux O, Lewis RF, Staples JE, et al. Yellow Fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med. 2014;11(5): e1001638.CrossRef Garske T, Van Kerkhove MD, Yactayo S, Ronveaux O, Lewis RF, Staples JE, et al. Yellow Fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med. 2014;11(5): e1001638.CrossRef
11.
go back to reference Hanley KA, Monath TP, Weaver SC, Rossi SL, Richman RL, Vasilakis N. Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus. Infect Genet Evol. 2013;19:292–311.CrossRef Hanley KA, Monath TP, Weaver SC, Rossi SL, Richman RL, Vasilakis N. Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus. Infect Genet Evol. 2013;19:292–311.CrossRef
12.
go back to reference Brown JE, Mcbride CS, Johnson P, Ritchie S, Paupy C, Bossin H, et al. Worldwide patterns of genetic differentiation imply multiple ‘domestications’ of Aedes aegypti, a major vector of human diseases. Proc R Soc B Biol Sci. 2011;278(1717):2446–54.CrossRef Brown JE, Mcbride CS, Johnson P, Ritchie S, Paupy C, Bossin H, et al. Worldwide patterns of genetic differentiation imply multiple ‘domestications’ of Aedes aegypti, a major vector of human diseases. Proc R Soc B Biol Sci. 2011;278(1717):2446–54.CrossRef
13.
go back to reference Chen J, Lu H. Yellow fever in China is still an imported disease. Biosci Trends. 2016;10(2):158–62.CrossRef Chen J, Lu H. Yellow fever in China is still an imported disease. Biosci Trends. 2016;10(2):158–62.CrossRef
16.
go back to reference Tsai TF, Lazuick JS, Ngah RW, Mafiamba PC, Quincke G, Monath TP. Investigation of a possible yellow fever epidemic and serosurvey for flavivirus infection in northern Cameroon, 1984. Bull World Health Organ. 1987;65(6):855–60.PubMedPubMedCentral Tsai TF, Lazuick JS, Ngah RW, Mafiamba PC, Quincke G, Monath TP. Investigation of a possible yellow fever epidemic and serosurvey for flavivirus infection in northern Cameroon, 1984. Bull World Health Organ. 1987;65(6):855–60.PubMedPubMedCentral
17.
go back to reference Vicens R, Robert V, Pignon D, Zeller H, Ghipponi PM, Digoutte JP. L’epidemie de fievre jaune de l’extreme nord du Cameroun en 1990: Premier isolement du virus amaril au Cameroun. Bull World Health Organ. 1993;71(2):173–6.PubMedPubMedCentral Vicens R, Robert V, Pignon D, Zeller H, Ghipponi PM, Digoutte JP. L’epidemie de fievre jaune de l’extreme nord du Cameroun en 1990: Premier isolement du virus amaril au Cameroun. Bull World Health Organ. 1993;71(2):173–6.PubMedPubMedCentral
18.
go back to reference Wiysonge CS, Nomo E, Mawo J, Ofal J, Mimbouga J, Ticha J, et al. Yellow fever control in Cameroon: where are we now and where are we going? BMC Med. 2008;6(June 2014). Wiysonge CS, Nomo E, Mawo J, Ofal J, Mimbouga J, Ticha J, et al. Yellow fever control in Cameroon: where are we now and where are we going? BMC Med. 2008;6(June 2014).
21.
go back to reference Domingo C, Patel P, Yillah J, Weidmann M, Méndez JA, Nakouné ER, et al. Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories. J Clin Microbiol. 2012;50(12):4054–60.CrossRef Domingo C, Patel P, Yillah J, Weidmann M, Méndez JA, Nakouné ER, et al. Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories. J Clin Microbiol. 2012;50(12):4054–60.CrossRef
22.
go back to reference Js P. A plaque technique for the titration of yellow fever virus and antisera. Trans R Soc Trop Med Hyg. 1959;53(6):458–64.CrossRef Js P. A plaque technique for the titration of yellow fever virus and antisera. Trans R Soc Trop Med Hyg. 1959;53(6):458–64.CrossRef
23.
go back to reference Spector S, Tauraso NM. Yellow fever virus. I. Development and evaluation of a plaque neutralization test. Appl Microbiol. 1968;16(11):1770–5.CrossRef Spector S, Tauraso NM. Yellow fever virus. I. Development and evaluation of a plaque neutralization test. Appl Microbiol. 1968;16(11):1770–5.CrossRef
24.
go back to reference Basile AJ, Goodman C, Horiuchi K, Laven J, Panella AJ, Kosoy O, Lanciotti RS, et al. Development and validation of an ELISA kit (YF MAC-HD) to detect IgM to yellow fever virus. J Virol Meth. 2015; 1(225):41–8. Basile AJ, Goodman C, Horiuchi K, Laven J, Panella AJ, Kosoy O, Lanciotti RS, et al. Development and validation of an ELISA kit (YF MAC-HD) to detect IgM to yellow fever virus. J Virol Meth. 2015; 1(225):41–8.
27.
go back to reference Programme Elargi de Vaccination Ministere de la Sante Publique Cameroon. Rapport D’activites 2016. 2016. Programme Elargi de Vaccination Ministere de la Sante Publique Cameroon. Rapport D’activites 2016. 2016.
30.
go back to reference Shearer FM, Moyes CL, Pigott DM, Brady OJ, Marinho F, Deshpande A, et al. Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis. Lancet Infect Dis. 2017;17(11):1209–17.CrossRef Shearer FM, Moyes CL, Pigott DM, Brady OJ, Marinho F, Deshpande A, et al. Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis. Lancet Infect Dis. 2017;17(11):1209–17.CrossRef
34.
go back to reference Kraemer MUG, Faria NR, Reiner RC, Golding N, Nikolay B, Stasse S, et al. Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015–16: a modelling study. Lancet Infect Dis. 2017;17(3):330–8.CrossRef Kraemer MUG, Faria NR, Reiner RC, Golding N, Nikolay B, Stasse S, et al. Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015–16: a modelling study. Lancet Infect Dis. 2017;17(3):330–8.CrossRef
36.
go back to reference Gibney KB, Edupuganti S, Panella AJ, Kosoy OI, Delorey MJ, Lanciotti RS, et al. Detection of anti-yellow fever virus immunoglobulin M antibodies at 3–4 years following yellow fever vaccination. Am J Trop Med Hyg. 2012;87(6):1112–5. Gibney KB, Edupuganti S, Panella AJ, Kosoy OI, Delorey MJ, Lanciotti RS, et al. Detection of anti-yellow fever virus immunoglobulin M antibodies at 3–4 years following yellow fever vaccination. Am J Trop Med Hyg. 2012;87(6):1112–5.
37.
go back to reference Niedrig M, Kürsteiner O, Herzog C, Sonnenberg K. Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin m (IgM) and IgG antibodies against yellow fever virus. Clin Vaccine Immunol. 2008;15(2):177–81.CrossRef Niedrig M, Kürsteiner O, Herzog C, Sonnenberg K. Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin m (IgM) and IgG antibodies against yellow fever virus. Clin Vaccine Immunol. 2008;15(2):177–81.CrossRef
38.
go back to reference Nemg Simo FB, SadoYousseu FB, EvounaMbarga A, Bigna JJ, Melong A, Ntoude A, et al. Investigation of an outbreak of dengue virus serotype 1 in a rural area of Kribi South Cameroon: a cross-sectional study. Intervirology. 2019;61(6):265–71.CrossRef Nemg Simo FB, SadoYousseu FB, EvounaMbarga A, Bigna JJ, Melong A, Ntoude A, et al. Investigation of an outbreak of dengue virus serotype 1 in a rural area of Kribi South Cameroon: a cross-sectional study. Intervirology. 2019;61(6):265–71.CrossRef
40.
go back to reference Fokam EB, Levai LD, Guzman H, Amelia PA, Titanji VPK, Tesh RB, et al. Silent circulation of arboviruses in Cameroon. East Afr Med J. 2010;87(6):262–8.PubMed Fokam EB, Levai LD, Guzman H, Amelia PA, Titanji VPK, Tesh RB, et al. Silent circulation of arboviruses in Cameroon. East Afr Med J. 2010;87(6):262–8.PubMed
41.
go back to reference Ndip LM, Bouyer DH, TravassosDa Rosa APA, Titanji VPK, Tesh RB, Walker DH. Acute spotted fever Rickettsiosis among febrile patients, Cameroon. Emerg Infect Dis. 2004;10(3):432–7.CrossRef Ndip LM, Bouyer DH, TravassosDa Rosa APA, Titanji VPK, Tesh RB, Walker DH. Acute spotted fever Rickettsiosis among febrile patients, Cameroon. Emerg Infect Dis. 2004;10(3):432–7.CrossRef
42.
go back to reference World Health Organization. World Health Organization, Global Strategy to Eliminate Yellow Fever; Document for SAGE; 2016: 2016. World Health Organization. World Health Organization, Global Strategy to Eliminate Yellow Fever; Document for SAGE; 2016: 2016.
Metadata
Title
Sustained circulation of yellow fever virus in Cameroon: an analysis of laboratory surveillance data, 2010–2020
Authors
Fredy Brice Simo Nemg
Ngu Njei Abanda
Martial Gide Yonga
Diane Ouapi
Ivis Ewang Samme
Marlise Dontsop Djoumetio
Marie Claire Endegue-Zanga
Maurice Demanou
Richard Njouom
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
Vaccination
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07407-1

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.